267 results on '"Dj Gubler"'
Search Results
2. A prM mutation that attenuates dengue virus replication in human cells enhances midgut infection in mosquitoes.
- Author
-
Choi ANX, Siriphanitchakorn T, Choy MM, Ooi JSG, Manuel M, Tan HC, Lin LZ, Yap X, Gubler DJ, and Ooi EE
- Subjects
- Animals, Humans, Dengue virology, Dengue transmission, Phylogeny, Cell Line, Protein Biosynthesis, Dengue Virus genetics, Dengue Virus physiology, Virus Replication genetics, Mutation genetics, Aedes virology
- Abstract
Dengue viruses (DENVs), like all viruses, evolve to perpetuate transmission of their species in their hosts. However, how DENV genetics influences dengue disease outbreaks remains poorly understood. Here, we examined isolates of the South Pacific dengue virus type 2 (DENV-2) that emerged in the 1970s and caused major dengue outbreaks in islands in this region until it reached Tonga, where only a few mild cases were reported. Phylogenetically, the DENV-2 strain isolated in Tonga segregated into a clade different from those clades infecting populations in other South Pacific islands. We found that this epidemiological observation could be explained by a single histidine-to-arginine substitution in position 86 of the premembrane (prM) protein of the Tonga DENV-2 strain. This mutation attenuated viral protein translation in mammalian cells but not in midgut cells of the mosquito vector Aedes aegypti . In mammalian cells, the prM mutation resulted in reduced translation of the viral genome and subsequent reduced virus replication. In contrast, in mosquito midgut cells, the prM mutation conferred a selective infection advantage, possibly because of the positively charged arginine residue introduced by the mutation. These findings provide molecular insights into the year-long silent transmission of attenuated DENV-2 in Tonga during the 1970s dengue outbreak in the South Pacific.
- Published
- 2024
- Full Text
- View/download PDF
3. Proceedings of the 6th Asia Dengue Summit, June 2023.
- Author
-
Srisawat N, Gubler DJ, Pangestu T, Limothai U, Thisyakorn U, Ismail Z, Goh D, Capeding MR, Bravo L, Yoksan S, Tantawichien T, Hadinegoro SR, Rafiq K, Picot VS, and Ooi EE
- Subjects
- Humans, Thailand, Public Health, World Health Organization, Asia, Southeastern epidemiology, Travel, Dengue epidemiology, Dengue prevention & control
- Abstract
The 6th Asia Dengue Summit (ADS) themed "Road Map to Zero Dengue Death" was held in Thailand from 15th-16th June 2023. The summit was hosted by Tropical Medicine Cluster, Chulalongkorn University, Bangkok, Thailand in conjunction with Queen Saovabha Memorial Institute, The Thai Red Cross Society; Faculty of Tropical Medicine, Mahidol University; and the Ministry of Public Health. The 6th ADS was convened by Asia Dengue Voice and Action (ADVA); Global Dengue and Aedes Transmitted Diseases Consortium (GDAC); Southeast Asian Ministers of Education Tropical Medicine and Public Health Network (SEAMEO TROPMED); Fondation Mérieux (FMx) and the International Society for Neglected Tropical Diseases (ISNTD). Dengue experts from academia and research, and representatives from the Ministries of Health, Regional and Global World Health Organization (WHO) and International Vaccine Institute (IVI) participated in the three-day summit. With more than 51 speakers and 451 delegates from over 24 countries, 10 symposiums, and 2 full days, the 6th ADS highlighted the growing threat of dengue and its antigenic evolution, flagged the urgent need to overcome vaccine hesitancy and misinformation crisis, and focused on dengue control policies, newer diagnostics, therapeutics and vaccines, travel-associated dengue, and strategies to improve community involvement., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Srisawat et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
4. Proceedings of the 5th Asia Dengue Summit.
- Author
-
Srisawat N, Gubler DJ, Pangestu T, Thisyakorn U, Ismail Z, Goh D, Capeding MR, Bravo L, Yoksan S, Tantawichien T, Hadinegoro SR, Rafiq K, Picot VS, and Ooi EE
- Abstract
The 5th Asia Dengue Summit, themed "Roll Back Dengue", was held in Singapore from 13 to 15 June 2022. The summit was co-convened by Asia Dengue Voice and Action (ADVA), Global Dengue and Aedes transmitted Diseases Consortium (GDAC), Southeast Asian Ministers of Education Tropical Medicine and Public Health Network (SEAMEO TROPMED), and the Fondation Mérieux (FMx). Dengue experts from academia and research and representatives from the Ministries of Health, Regional and Global World Health Organization (WHO), and International Vaccine Institute (IVI) participated in the three-day summit. With more than 270 speakers and delegates from over 14 countries, 12 symposiums, and 3 full days, the 5th ADS highlighted the growing threat of dengue, shared innovations and strategies for successful dengue control, and emphasized the need for multi-sectoral collaboration to control dengue.
- Published
- 2023
- Full Text
- View/download PDF
5. World Dengue Day: A call for action.
- Author
-
Srisawat N, Thisyakorn U, Ismail Z, Rafiq K, and Gubler DJ
- Subjects
- Humans, Neglected Diseases epidemiology, Pandemics, COVID-19, Dengue epidemiology, Dengue prevention & control, Vaccines
- Abstract
Commemorating the 2021 ASEAN Dengue Day and advocacy for World Dengue Day, the International Society for Neglected Tropical Diseases (ISNTD) and Asian Dengue Voice and Action (ADVA) Group jointly hosted the ISNTD-ADVA World Dengue Day Forum-Cross Sector Synergies in June 2021. The forum aimed to achieve international and multisectoral coordination to consolidate global dengue control and prevention efforts, share best practices and resources, and improve global preparedness. The forum featured experts around the world who shared their insight, research experience, and strategies to tackle the growing threat of dengue. Over 2,000 healthcare care professionals, researchers, epidemiologists, and policy makers from 59 countries attended the forum, highlighting the urgency for integrated, multisectoral collaboration between health, environment, education, and policy to continue the march against dengue. Sustained vector control, environmental management, surveillance improved case management, continuous vaccine advocacy and research, capacity building, political commitment, and community engagement are crucial components of dengue control. A coordinated strategy based on science, transparency, timely and credible communication, and understanding of human behavior is needed to overcome vaccine hesitancy, a major health risk further magnified by the COVID-19 pandemic. The forum announced a strong call to action to establish World Dengue Day to improve global awareness, share best practices, and prioritize preparedness in the fight against dengue., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
6. The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines.
- Author
-
Bettis AA, L'Azou Jackson M, Yoon IK, Breugelmans JG, Goios A, Gubler DJ, and Powers AM
- Subjects
- Aedes virology, Animals, Disease Outbreaks, Humans, Mosquito Vectors virology, Neglected Diseases epidemiology, Neglected Diseases virology, Seroepidemiologic Studies, Viral Vaccines immunology, Chikungunya Fever epidemiology, Chikungunya Fever prevention & control, Chikungunya virus immunology, Vaccine Development
- Abstract
Chikungunya fever is an acute febrile illness that is often associated with severe polyarthralgia in humans. The disease is caused by chikungunya virus (CHIKV), a mosquito-borne alphavirus. Since its reemergence in 2004, the virus has spread throughout the tropical world and several subtropical areas affecting millions of people to become a global public health issue. Given the significant disease burden, there is a need for medical countermeasures and several vaccine candidates are in clinical development. To characterize the global epidemiology of chikungunya and inform vaccine development, we undertook a systematic literature review in MEDLINE and additional public domain sources published up to June 13, 2020 and assessed epidemiological trends from 1999 to 2020. Observational studies addressing CHIKV epidemiology were included and studies not reporting primary data were excluded. Only descriptive analyses were conducted. Of 3,883 relevant sources identified, 371 were eligible for inclusion. 46% of the included studies were published after 2016. Ninety-seven outbreak reports from 45 countries and 50 seroprevalence studies from 31 countries were retrieved, including from Africa, Asia, Oceania, the Americas, and Europe. Several countries reported multiple outbreaks, but these were sporadic and unpredictable. Substantial gaps in epidemiological knowledge were identified, specifically granular data on disease incidence and age-specific infection rates. The retrieved studies revealed a diversity of methodologies and study designs, reflecting a lack of standardized procedures used to characterize this disease. Nevertheless, available epidemiological data emphasized the challenges to conduct vaccine efficacy trials due to disease unpredictability. A better understanding of chikungunya disease dynamics with appropriate granularity and better insights into the duration of long-term population immunity is critical to assist in the planning and success of vaccine development efforts pre and post licensure., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
7. Implementation strategies for the first licensed dengue vaccine: A meeting report.
- Author
-
Fongwen N, Delrieu I, Ham LH, Gubler DJ, Durbin A, Ooi EE, Peeling RW, Flasche S, Hartigan-Go K, Clifford S, Martinez CT, de Lamballerie X, Barnighausen T, and Wilder-Smith A
- Subjects
- Antibodies, Viral, Cost-Benefit Analysis, Humans, Vaccines, Attenuated, Dengue prevention & control, Dengue Vaccines, Dengue Virus
- Abstract
Dengue vaccination would enhance the control of dengue, one of the most frequent vector-borne viral diseases globally. CYD-TDV is the first dengue vaccine to be licensed, but global uptake has been hampered due to its use being limited to seropositive persons aged 9 years and above, and the need for a 3-dose schedule. The Partnership for Dengue Control (PDC) organized a meeting with key opinion leaders and stakeholders to deliberate on implementation strategies for the use of CYD-TDV. New data have emerged that support the shortening of the primary schedule from a 3 to 2 dose schedule, extending the age range below 9 to 6 years of age, and expanding the indication from endemic populations to also include travelers to endemic areas. Cost-effectiveness may improve with the modified 2-dose regimen and with multiple testing. Strategies to implement a dengue vaccination program have been developed, in particular school-based strategies. A range of delivery scenarios can then be considered, using various settings for each step of the intervention. However, several challenges remain, including communication about limiting the use of this vaccine to seropositive individuals only. Affordability will vary from country to country, as will government commitment and community acceptance. Well-tailored communication strategies that target key stakeholders are expected to make up a significant part of any future dengue vaccination program., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [RP is Director of the International Diagnostics Centre. AD is clinical trial principal investigator for the NIH dengue vaccine. EEO has served on various advisory boards for dengue vaccine developers including Sanofi Pasteur. AWS serves as consultant to WHO; statements presented here reflect her views and not necessarily those of WHO. KHG was a Department of Health Philippines official and one of many respondents to legal cases in the Philippines in relations to Dengvaxia vaccination causing deaths in children. ID works for the company EpiLinks, that receives funding from Fondation Mérieux and Sanofi Pasteur to develop a toolkit for dengue vaccine implementation. CTM has recerived honoraria for consultancies from Sanofi Pasteur.], (Copyright © 2021.)
- Published
- 2021
- Full Text
- View/download PDF
8. Target product profile for a dengue pre-vaccination screening test.
- Author
-
Fongwen N, Wilder-Smith A, Gubler DJ, Ooi EE, T Salvana EM, de Lamballerie X, Olliaro PL, and Peeling RW
- Subjects
- Antibodies, Viral blood, Antibodies, Viral immunology, Dengue immunology, Humans, Mass Screening methods, Reference Standards, Sensitivity and Specificity, Vaccines, Attenuated, Dengue diagnosis, Dengue prevention & control, Dengue Vaccines immunology, Point-of-Care Testing, Serologic Tests methods, Vaccination
- Abstract
With increasing geographic spread, frequency, and magnitude of outbreaks, dengue continues to pose a major public health threat worldwide. Dengvaxia, a dengue live-attenuated tetravalent vaccine, was licensed in 2015, but post hoc analyses of long-term data showed serostatus-dependent vaccine performance with an excess risk of hospitalized and severe dengue in seronegative vaccine recipients. The World Health Organization (WHO) recommended that only persons with evidence of past dengue infection should receive the vaccine. A test for pre-vaccination screening for dengue serostatus is needed. To develop the target product profile (TPP) for a dengue pre-vaccination screening test, face-to-face consultative meetings were organized with follow-up regional consultations. A technical working group was formed to develop consensus on a reference test against which candidate pre-vaccination screening tests could be compared. The group also reviewed current diagnostic landscape and the need to accelerate the evaluation, regulatory approval, and policy development of tests that can identify seropositive individuals and maximize public health impact of vaccination while avoiding the risk of hospitalization in dengue-naive individuals. Pre-vaccination screening strategies will benefit from rapid diagnostic tests (RDTs) that are affordable, sensitive, and specific and can be used at the point of care (POC). The TPP described the minimum and ideal characteristics of a dengue pre-vaccination screening RDT with an emphasis on high specificity. The group also made suggestions for accelerating access to these RDTs through streamlining regulatory approval and policy development. Risk and benefit based on what can be achieved with RDTs meeting minimal and optimal characteristics in the TPP across a range of seroprevalences were defined. The final choice of RDTs in each country will depend on the performance of the RDT, dengue seroprevalence in the target population, tolerance of risk, and cost-effectiveness., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
9. Th1-Polarized, Dengue Virus-Activated Human Mast Cells Induce Endothelial Transcriptional Activation and Permeability.
- Author
-
Syenina A, Saron WAA, Jagaraj CJ, Bibi S, Arock M, Gubler DJ, Rathore APS, Abraham SN, and St John AL
- Subjects
- Biomarkers, Capillary Permeability, Cell Degranulation immunology, Dengue virology, Endothelial Cells, Endothelium, Vascular immunology, Fluorescent Antibody Technique, Gene Expression Profiling, Histocytochemistry, Host-Pathogen Interactions immunology, Humans, Lymphocyte Activation, Macrophages immunology, Macrophages metabolism, Mast Cells cytology, Dengue immunology, Dengue metabolism, Dengue Virus immunology, Endothelium, Vascular metabolism, Mast Cells physiology, Th1 Cells physiology, Transcriptional Activation
- Abstract
Dengue virus (DENV), an arbovirus, strongly activates mast cells (MCs), which are key immune cells for pathogen immune surveillance. In animal models, MCs promote clearance of local peripheral DENV infections but, conversely, also promote pathological vascular leakage when widely activated during systemic DENV infection. Since DENV is a human pathogen, we sought to ascertain whether a similar phenomenon could occur in humans by characterizing the products released by human MCs (huMCs) upon direct (antibody-independent) DENV exposure, using the phenotypically mature huMC line, ROSA. DENV did not productively infect huMCs but prompted huMC release of proteases and eicosanoids and induced a Th1-polarized transcriptional profile. In co-culture and trans-well systems, huMC products activated human microvascular endothelial cells, involving transcription of vasoactive mediators and increased monolayer permeability. This permeability was blocked by MC-stabilizing drugs, or limited by drugs targeting certain MC products. Thus, MC stabilizers are a viable strategy to limit MC-promoted vascular leakage during DENV infection in humans.
- Published
- 2020
- Full Text
- View/download PDF
10. Preventing Dengue Epidemics during the COVID-19 Pandemic.
- Author
-
Wilder-Smith A, Tissera H, Ooi EE, Coloma J, Scott TW, and Gubler DJ
- Subjects
- Animals, Betacoronavirus, COVID-19, Community Participation, Culicidae virology, Humans, Mosquito Control, Pandemics, Public Health, SARS-CoV-2, Tropical Climate, Coronavirus Infections epidemiology, Dengue prevention & control, Pneumonia, Viral epidemiology
- Published
- 2020
- Full Text
- View/download PDF
11. The Lancet Commission on dengue and other Aedes-transmitted viral diseases.
- Author
-
Wilder-Smith A, Lindsay SW, Scott TW, Ooi EE, Gubler DJ, and Das P
- Subjects
- Animals, Delivery of Health Care, Integrated organization & administration, Dengue epidemiology, Dengue prevention & control, Dengue transmission, Epidemics, Global Health statistics & numerical data, Humans, Mosquito Control methods, Vector Borne Diseases epidemiology, Vector Borne Diseases transmission, Aedes virology, Mosquito Vectors, Vector Borne Diseases prevention & control
- Published
- 2020
- Full Text
- View/download PDF
12. Geospatial analysis of dengue emergence in rural areas in the Southern Province of Sri Lanka.
- Author
-
Mutucumarana CP, Bodinayake CK, Nagahawatte A, Devasiri V, Kurukulasooriya R, Anuradha T, De Silva AD, Janko MM, Østbye T, Gubler DJ, Woods CW, Reller ME, Tillekeratne LG, and Lantos PM
- Subjects
- Cross-Sectional Studies, Fever, Humans, Public Health, Sri Lanka epidemiology, Dengue epidemiology
- Abstract
Background: Dengue is a major cause of acute febrile illness in Sri Lanka. Dengue has historically been considered an urban disease. In 2012-2013, we documented that acute dengue was surprisingly associated with self-reported rural residence in the Southern Province of Sri Lanka., Methods: Patients admitted with an acute febrile illness were enrolled from June 2012-May 2013 in a cross-sectional surveillance study at the largest tertiary care hospital in the Southern Province. Acute dengue was diagnosed by serology and virology testing. Site visits were performed to collect residential geographical coordinates. Spatial variation in odds of acute dengue was modeled using a spatial generalized additive model predicted onto a grid of coordinate pairs covering the Southern Province., Results: Of 800 patients, 333 (41.6%) had laboratory-confirmed acute dengue. Dengue was spatially heterogeneous (local probability of acute dengue 0.26 to 0.42). There were higher than average odds of acute dengue in the rural northeast of the Southern Province and lower than average odds in the urbanized southwest of the Southern Province, including the city Galle., Conclusions: Our study further affirms the emergence of dengue in rural southern Sri Lanka and highlights both the need for real-time geospatial analyses to optimize public health activities as well as the importance of strengthening dengue surveillance in non-urban areas., (© The Author(s) 2020. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.)
- Published
- 2020
- Full Text
- View/download PDF
13. Arboviruses: A global public health threat.
- Author
-
Girard M, Nelson CB, Picot V, and Gubler DJ
- Subjects
- Africa, Americas, Animals, Asia, Congresses as Topic, Europe, France, Humans, Public Health, Arbovirus Infections epidemiology, Arboviruses, Global Health
- Abstract
A conference on «ARBOVIRUSES, A GLOBAL PUBLIC HEALTH THREAT» was organized on June 20-22, 2018 at the Merieux Foundation Conference Center in Veyrier du Lac, France, to review and raise awareness to the global public health threat of epidemic arboviruses, and to advance the discussion on the control and prevention of arboviral diseases. The presentations by scientists and public health officials from Asia, the Americas, Europe and Africa strengthened the notion that arboviral diseases of both humans and domestic animals are progressively becoming dominant public health problems in the world. The repeated occurrence of recent deadly epidemics strongly reinforces the call for action against these viral diseases, and the need for developing effective vaccines, drugs, vector control tools and strong prevention programs., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2020.)
- Published
- 2020
- Full Text
- View/download PDF
14. Recombination of B- and T-cell epitope-rich loci from Aedes- and Culex-borne flaviviruses shapes Zika virus epidemiology.
- Author
-
Gaunt MW, Gubler DJ, Pettersson JH, Kuno G, Wilder-Smith A, de Lamballerie X, Gould EA, and Falconar AK
- Subjects
- Aedes virology, Animals, B-Lymphocytes immunology, Computer Simulation, Cross Reactions, Culex virology, Dengue Virus genetics, Dengue Virus immunology, Epitopes, B-Lymphocyte immunology, Epitopes, T-Lymphocyte immunology, Humans, Phylogeny, Proteome, Recombination, Genetic, T-Lymphocytes immunology, Viral Proteins immunology, Zika Virus genetics, Zika Virus Infection immunology, Epitopes, B-Lymphocyte genetics, Epitopes, T-Lymphocyte genetics, Viral Proteins genetics, Zika Virus immunology, Zika Virus Infection epidemiology
- Abstract
Sporadic human Zika virus (ZIKV) infections have been recorded in Africa and Asia since the 1950s. Major epidemics occurred only after ZIKV emerged in the Pacific islands and spread to the Americas. Specific biological determinants of the explosive epidemic nature of ZIKV have not been identified. Phylogenetic studies revealed incongruence in ZIKV placement in relation to Aedes-borne dengue viruses (DENV) and Culex-borne flaviviruses. We hypothesized that this incongruence reflects interspecies recombination resulting in ZIKV evasion of cross-protective T-cell immunity. We investigated ZIKV phylogenetic incongruence in relation to: DENV T-cell epitope maps experimentally identified ex vivo, published B-cell epitope loci, and CD8
+ T-cell epitopes predicted in silico for mosquito-borne flaviviruses. Our findings demonstrate that the ZIKV proteome is a hybrid of Aedes-borne DENV proteins interspersed amongst Culex-borne flavivirus proteins derived through independent interspecies recombination events. These analyses infer that DENV-associated proteins in the ZIKV hybrid proteome generated immunodominant human B-cell responses, whereas ZIKV recombinant derived Culex-borne flavivirus-associated proteins generated immunodominant CD8+ and/or CD4+ T-cell responses. In silico CD8+ T-cell epitope ZIKV cross-reactive prediction analyses verified this observation. We propose that by acquiring cytotoxic T-cell epitope-rich regions from Culex-borne flaviviruses, ZIKV evaded DENV-generated T-cell immune cross-protection. Thus, Culex-borne flaviviruses, including West Nile virus and Japanese encephalitis virus, might induce cross-protective T-cell responses against ZIKV. This would explain why explosive ZIKV epidemics occurred in DENV-endemic regions of Micronesia, Polynesia and the Americas where Culex-borne flavivirus outbreaks are infrequent and why ZIKV did not cause major epidemics in Asia where Culex-borne flaviviruses are widespread., Competing Interests: Declaration of competing interest No potential conflict of interest was reported by the authors., (Crown Copyright © 2019. Published by Elsevier B.V. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
15. Dengue pre-vaccination serology screening for the use of Dengvaxia®.
- Author
-
Hunsperger E, Peeling R, Gubler DJ, and Ooi EE
- Subjects
- Antibodies, Viral blood, Dengue immunology, Dengue Virus immunology, Humans, Predictive Value of Tests, Seroepidemiologic Studies, Vaccination, Dengue diagnosis, Dengue prevention & control, Dengue Vaccines administration & dosage, Serologic Tests, Travel
- Published
- 2019
- Full Text
- View/download PDF
16. Is Dengvaxia a useful vaccine for dengue endemic areas?
- Author
-
Gubler DJ and Halstead SB
- Subjects
- Dengue immunology, Dengue virology, Dengue Vaccines adverse effects, Humans, Dengue prevention & control, Dengue Vaccines administration & dosage, Dengue Virus immunology, Endemic Diseases prevention & control
- Abstract
Competing Interests: Competing interests: DJG is a patent holder (TAK-003 vaccine) and temporary adviser to Takeda, Sanofi Pasteur, and Merck. During the past three years SBH has served as short term consultant to Takeda, Sanofi Pasteur, GlaxoSmithKline, and Merck.
- Published
- 2019
- Full Text
- View/download PDF
17. What is the prospect of a safe and effective dengue vaccine for travellers?
- Author
-
Durbin AP and Gubler DJ
- Subjects
- Dengue Vaccines adverse effects, Dengue Virus immunology, Drug Administration Schedule, Humans, Travel, Dengue prevention & control, Dengue Vaccines immunology
- Published
- 2019
- Full Text
- View/download PDF
18. Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: A meeting report.
- Author
-
Wilder-Smith A, Smith PG, Luo R, Kelly-Cirino C, Curry D, Larson H, Durbin A, Chu M, Tharmaphornpilas P, Ng LC, Sartori AMC, Luna EJA, Gubler DJ, España G, Yoon IK, and Flasche S
- Subjects
- Adolescent, Adult, Antibodies, Viral immunology, Child, Dengue immunology, Dengue microbiology, Dengue prevention & control, Dengue Vaccines immunology, Dengue Virus, Humans, Immunization Programs methods, Public Health, Seroepidemiologic Studies, Vaccines, Attenuated therapeutic use, World Health Organization, Young Adult, Dengue Vaccines therapeutic use
- Abstract
The first licensed dengue vaccine, CYD-TDV (Dengvaxia) is efficacious in seropositive individuals, but increases the risk for severe dengue in seronegative persons about two years after administration of the first dose. For countries considering the introduction of Dengvaxia, WHO recommends a pre-vaccination screening strategy whereby only persons with evidence of a past dengue infection would be vaccinated. Policy-makers need to consider the risk-benefit of vaccination strategies based on such screening tests, the optimal age to introduce the vaccine, communication and implementation strategies. To address these questions, the Global Dengue and Aedes-transmitted diseases Consortium (GDAC) organized a 3-day workshop in January 2019 with country representatives from Asia and Latin America. The meeting discussions highlighted many challenges in introducing Dengvaxia, in terms of screening test characteristics, costs of such tests combined with a 3-dose schedule, logistics, achieving high coverage rates, vaccine confidence and communication; more challenges than for any other vaccine introduction programme. A screening test would require a high specificity to minimize individual risk, and at the same time high sensitivity to maximize individual and population benefit. The underlying seroprevalence dependent positive predictive value is the best indicator for an acceptable safety profile of a pre-vaccination screening strategy. The working groups discussed many possible implementation strategies. Addressing the bottlenecks in school-based vaccine introduction for Dengvaxia will also benefit other vaccines such as HPV and booster doses for tetanus and pertussis. Levels of public trust are highly variable and context specific, and understanding of population perceptions and concerns is essential to tailor interventions, monitor and mitigate risks., (Copyright © 2019.)
- Published
- 2019
- Full Text
- View/download PDF
19. Dengue virus-elicited tryptase induces endothelial permeability and shock.
- Author
-
Rathore AP, Mantri CK, Aman SA, Syenina A, Ooi J, Jagaraj CJ, Goh CC, Tissera H, Wilder-Smith A, Ng LG, Gubler DJ, and St John AL
- Subjects
- Animals, Benzamidines, Cell Line, Dengue drug therapy, Dengue pathology, Dengue virology, Endothelium, Vascular pathology, Endothelium, Vascular virology, Guanidines pharmacology, Humans, Mast Cells pathology, Mast Cells virology, Mice, Shock drug therapy, Shock pathology, Shock virology, Tight Junctions pathology, Tryptases antagonists & inhibitors, Tryptases genetics, Capillary Permeability, Dengue enzymology, Dengue Virus metabolism, Endothelium, Vascular enzymology, Mast Cells enzymology, Shock enzymology, Tight Junctions metabolism, Tryptases metabolism
- Abstract
Dengue virus (DENV) infection causes a characteristic pathology in humans involving dysregulation of the vascular system. In some patients with dengue hemorrhagic fever (DHF), vascular pathology can become severe, resulting in extensive microvascular permeability and plasma leakage into tissues and organs. Mast cells (MCs), which line blood vessels and regulate vascular function, are able to detect DENV in vivo and promote vascular leakage. Here, we identified that a MC-derived protease, tryptase, is consequential for promoting vascular permeability during DENV infection, through inducing breakdown of endothelial cell tight junctions. Injected tryptase alone was sufficient to induce plasma loss from the circulation and hypovolemic shock in animals. A potent tryptase inhibitor, nafamostat mesylate, blocked DENV-induced vascular leakage in vivo. Importantly, in two independent human dengue cohorts, tryptase levels correlated with the grade of DHF severity. This study defines an immune mechanism by which DENV can induce vascular pathology and shock.
- Published
- 2019
- Full Text
- View/download PDF
20. Application of a targeted-enrichment methodology for full-genome sequencing of Dengue 1-4, Chikungunya and Zika viruses directly from patient samples.
- Author
-
Kamaraj US, Tan JH, Xin Mei O, Pan L, Chawla T, Uehara A, Wang LF, Ooi EE, Gubler DJ, Tissera H, Ng LC, Wilder-Smith A, de Sessions PF, Barkham T, Anderson DE, and Sessions OM
- Subjects
- Cell Line, Chikungunya Fever diagnosis, Chikungunya virus isolation & purification, Coinfection epidemiology, Coinfection transmission, Computational Biology, Dengue diagnosis, Dengue Virus isolation & purification, Disease Outbreaks, Genomics, High-Throughput Nucleotide Sequencing, Humans, Singapore epidemiology, Sri Lanka epidemiology, Zika Virus isolation & purification, Zika Virus Infection diagnosis, Chikungunya virus genetics, Dengue Virus genetics, Genome, Viral, Nucleic Acid Amplification Techniques methods, Zika Virus genetics
- Abstract
The frequency of epidemics caused by Dengue viruses 1-4, Zika virus and Chikungunya viruses have been on an upward trend in recent years driven primarily by uncontrolled urbanization, mobility of human populations and geographical spread of their shared vectors, Aedes aegypti and Aedes albopictus. Infections by these viruses present with similar clinical manifestations making them challenging to diagnose; this is especially difficult in regions of the world hyperendemic for these viruses. In this study, we present a targeted-enrichment methodology to simultaneously sequence the complete viral genomes for each of these viruses directly from clinical samples. Additionally, we have also developed a customized computational tool (BaitMaker) to design these enrichment baits. This methodology is robust in its ability to capture diverse sequences and is amenable to large-scale epidemiological studies. We have applied this methodology to two large cohorts: a febrile study based in Colombo, Sri Lanka taken during the 2009-2015 dengue epidemic (n = 170) and another taken during the 2016 outbreak of Zika virus in Singapore (n = 162). Results from these studies indicate that we were able to cover an average of 97.04% ± 0.67% of the full viral genome from samples in these cohorts. We also show detection of one DENV3/ZIKV co-infected patient where we recovered full genomes for both viruses., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
21. Yellow fever: is Asia prepared for an epidemic?
- Author
-
Wilder-Smith A, Lee V, and Gubler DJ
- Subjects
- Asia, Humans, Public Health, Yellow fever virus, Epidemics, Yellow Fever epidemiology
- Published
- 2019
- Full Text
- View/download PDF
22. Development of standard clinical endpoints for use in dengue interventional trials: introduction and methodology.
- Author
-
Jaenisch T, Hendrickx K, Erpicum M, Agulto L, Tomashek KM, Dempsey W, Siqueira JB, Marks MA, Fay MP, Laughlin C, L'Azou M, Leo YS, Narvaez F, Teyssou R, Thomas SJ, Tissera H, Wallace D, Wilder-Smith A, Gubler DJ, and Cassetti MC
- Subjects
- Delphi Technique, Dengue therapy, Dengue Vaccines administration & dosage, Endpoint Determination standards, Hospitalization statistics & numerical data, Humans, Outcome Assessment, Health Care methods, Outcome Assessment, Health Care standards, Reproducibility of Results, Clinical Trials as Topic, Dengue prevention & control, Dengue Vaccines therapeutic use, Endpoint Determination methods
- Abstract
Background: As increasing numbers of dengue vaccines and therapeutics are in clinical development, standardized consensus clinical endpoint definitions are urgently needed to assess the efficacy of different interventions with respect to disease severity. We aimed to convene dengue experts representing various sectors and dengue endemic areas to review the literature and propose clinical endpoint definitions for moderate and severe disease based on the framework provided by the WHO 2009 classification., Methods: The endpoints were first proposed and discussed in a structured expert consultation. After that, the Delphi method was carried out to assess the usefulness, validity and feasibility of the standardized clinical disease endpoints for interventional dengue research., Results: Most respondents (> 80%) agreed there is a need for both standardized clinical endpoints and operationalization of severe endpoints. Most respondents (67%) felt there is utility for moderate severity endpoints, but cited challenges in their development. Hospitalization as a moderate endpoint of disease severity or measure of public health impact was deemed to be useful by only 47% of respondents, but 89% felt it could bring about supplemental information if carefully contextualized according to data collection setting. Over half of the respondents favored alignment of the standard endpoints with the WHO guidelines (58%), but cautioned that the endpoints could have ramifications for public health practice. In terms of data granularity of the endpoints, there was a slight preference for a categorical vs numeric system (e.g. 1-10) (47% vs 34%), and 74% of respondents suggested validating the endpoints using large prospective data sets., Conclusion: The structured consensus-building process was successful taking into account the history of the debate around potential endpoints for severe dengue. There is clear support for the development of standardized endpoints for interventional clinical research and the need for subsequent validation with prospective data sets. Challenges include the complexity of developing moderate disease research endpoints for dengue.
- Published
- 2018
- Full Text
- View/download PDF
23. Unexpected outbreaks of arbovirus infections: lessons learned from the Pacific and tropical America.
- Author
-
Musso D, Rodriguez-Morales AJ, Levi JE, Cao-Lormeau VM, and Gubler DJ
- Subjects
- Animals, Birds, Global Health, Humans, Tropical Climate, Arbovirus Infections epidemiology, Arbovirus Infections veterinary, Arboviruses isolation & purification, Disease Outbreaks
- Abstract
Pandemic arboviruses have emerged as a major global health problem in the past four decades. Predicting where and when the next arbovirus epidemic will occur is a challenge, but history suggests that arboviral black swan events (epidemics that are difficult to predict and that have an extreme effect) will continue to occur as urban growth and globalisation expand. We briefly review unexpected arbovirus epidemics that have occurred in the past 50 years, with emphasis on the American and Pacific regions, to illustrate their unpredictability, and to highlight the need for improved global preparedness, including laboratory-based surveillance, prevention, and control programmes., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
24. Development of standard clinical endpoints for use in dengue interventional trials.
- Author
-
Tomashek KM, Wills B, See Lum LC, Thomas L, Durbin A, Leo YS, de Bosch N, Rojas E, Hendrickx K, Erpicum M, Agulto L, Jaenisch T, Tissera H, Suntarattiwong P, Collers BA, Wallace D, Schmidt AC, Precioso A, Narvaez F, Thomas SJ, Edelman R, Siqueira JB, Cassetti MC, Dempsey W, and Gubler DJ
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antiviral Agents therapeutic use, Child, Child, Preschool, Clinical Trials as Topic standards, Dengue diagnosis, Dengue pathology, Dengue Vaccines immunology, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Treatment Outcome, Young Adult, Clinical Trials as Topic methods, Dengue drug therapy, Dengue prevention & control, Endpoint Determination
- Abstract
Dengue is a major public health problem worldwide. Although several drug candidates have been evaluated in randomized controlled trials, none has been effective and at present, early recognition of severe dengue and timely supportive care are used to reduce mortality. While the first dengue vaccine was recently licensed, and several other candidates are in late stage clinical trials, future decisions regarding widespread deployment of vaccines and/or therapeutics will require evidence of product safety, efficacy and effectiveness. Standard, quantifiable clinical endpoints are needed to ensure reproducibility and comparability of research findings. To address this need, we established a working group of dengue researchers and public health specialists to develop standardized endpoints and work towards consensus opinion on those endpoints. After discussion at two working group meetings and presentations at international conferences, a Delphi methodology-based query was used to finalize and operationalize the clinical endpoints. Participants were asked to select the best endpoints from proposed definitions or offer revised/new definitions, and to indicate whether contributing items should be designated as optional or required. After the third round of inquiry, 70% or greater agreement was reached on moderate and severe plasma leakage, moderate and severe bleeding, acute hepatitis and acute liver failure, and moderate and severe neurologic disease. There was less agreement regarding moderate and severe thrombocytopenia and moderate and severe myocarditis. Notably, 68% of participants agreed that a 50,000 to 20,000 mm3 platelet range be used to define moderate thrombocytopenia; however, they remained divided on whether a rapid decreasing trend or one platelet count should be case defining. While at least 70% agreement was reached on most endpoints, the process identified areas for further evaluation and standardization within the context of ongoing clinical studies. These endpoints can be used to harmonize data collection and improve comparability between dengue clinical trials., Competing Interests: Beth-Ann G. Coller is an employee, shareholder and patent inventor of Merck & Co., Inc., Kenilworth, New Jersey, United States of America. Robert Edelman is a paid consultant to Takeda Pharmaceutical Company vaccine trials for service as Chairman of the Data and Safety Monitoring Board (DSMB) of Takeda's Tetravalent Dengue Vaccine Program. Alexander C. Schmidt is an employee and shareholder of the GlaxoSmithKline plc (GSK), Brentford, London, United Kingdom. Stephen J. Thomas has performed both paid and unpaid consultations and safety reviews for GSK Vaccines, Merck, Takeda, Sanofi Pasteur, Chugai Pharma, Themisbio, and Primevax. Derek Wallace is an employee of Takeda Pharmaceuticals International AG, Zurich, Switzerland. Bridget Wills is a paid consultant on the DSMB for the Takeda vaccine trials. No other authors have declared that a competing interest exists.
- Published
- 2018
- Full Text
- View/download PDF
25. Potential yellow fever epidemics in unexposed populations.
- Author
-
Gubler DJ
- Subjects
- Animals, Global Health, Humans, Public Health, Yellow Fever prevention & control, Disease Outbreaks, Epidemics, Yellow Fever epidemiology
- Published
- 2018
- Full Text
- View/download PDF
26. Potential Point-of-Care Testing for Dengue Virus in the Field.
- Author
-
Wang WK and Gubler DJ
- Subjects
- Dengue virology, Humans, Reproducibility of Results, Dengue diagnosis, Dengue Virus classification, Dengue Virus genetics, Molecular Diagnostic Techniques methods, Point-of-Care Testing, Polymerase Chain Reaction methods
- Abstract
The four serotypes of dengue virus (DENV) cause one of the most important and rapidly emerging mosquito-borne viral diseases in humans. Of the currently available diagnostic tests for dengue, the reverse transcription-PCR (RT-PCR) assay is the most sensitive and specific, and so it is commonly used as the gold standard. However, the requirement of a sophisticated and expensive thermal cycler makes it very difficult to use as a point-of-care diagnostic test in resource-limited regions where dengue is endemic. Tsai et al. (J Clin Microbiol 56:e01865-17, 2018, https://doi.org/10.1128/JCM.01865-17) report the analytical and clinical performances of a reverse transcription-insulated isothermal PCR (RT-iiPCR) assay with a portable nucleic acid analyzer for rapid detection of the four DENV serotypes; its reproducibility and complete agreement on clinical samples with the multiplex RT-PCR assay developed by the Centers for Disease Control and Prevention suggest that the dengue RT-iiPCR is a potential point-of-care test. Compared with other DENV RNA detection methods, the unique isothermal PCR design of RT-iiPCR, together with further improvements, would represent a promising new type of field-deployable diagnostic test for dengue., (Copyright © 2018 American Society for Microbiology.)
- Published
- 2018
- Full Text
- View/download PDF
27. Innovative and New Approaches to Laboratory Diagnosis of Zika and Dengue: A Meeting Report.
- Author
-
Goncalves A, Peeling RW, Chu MC, Gubler DJ, de Silva AM, Harris E, Murtagh M, Chua A, Rodriguez W, Kelly C, and Wilder-Smith A
- Subjects
- Antibodies, Viral immunology, Consumer Product Safety, Dengue history, Dengue virology, Dengue Virus genetics, Dengue Virus immunology, Dengue Virus isolation & purification, Enzyme-Linked Immunosorbent Assay history, Enzyme-Linked Immunosorbent Assay methods, Enzyme-Linked Immunosorbent Assay trends, History, 20th Century, History, 21st Century, Humans, Population Surveillance, Reverse Transcriptase Polymerase Chain Reaction history, Reverse Transcriptase Polymerase Chain Reaction methods, Reverse Transcriptase Polymerase Chain Reaction trends, Sensitivity and Specificity, Zika Virus genetics, Zika Virus immunology, Zika Virus isolation & purification, Zika Virus Infection history, Zika Virus Infection virology, Antibodies, Viral blood, Dengue diagnosis, Zika Virus Infection diagnosis
- Abstract
Epidemics of dengue, Zika, and other arboviral diseases are increasing in frequency and severity. Current efforts to rapidly identify and manage these epidemics are limited by the short diagnostic window in acute infection, the extensive serologic cross-reactivity among flaviviruses, and the lack of point-of-care diagnostic tools to detect these viral species in primary care settings. The Partnership for Dengue Control organized a workshop to review the current landscape of Flavivirus diagnostic tools, identified current gaps, and developed strategies to accelerate the adoption of promising novel technologies into national programs. The rate-limiting step to bringing new diagnostic tools to the market is access to reference materials and well-characterized clinical samples to facilitate performance evaluation. We suggest the creation of an international laboratory-response consortium for flaviviruses with a decentralized biobank of well-characterized samples to facilitate assay validation. Access to proficiency panels are needed to ensure quality control, in additional to in-country capacity building.
- Published
- 2018
- Full Text
- View/download PDF
28. Evaluation of the WHO 2009 classification for diagnosis of acute dengue in a large cohort of adults and children in Sri Lanka during a dengue-1 epidemic.
- Author
-
Bodinayake CK, Tillekeratne LG, Nagahawatte A, Devasiri V, Kodikara Arachchi W, Strouse JJ, Sessions OM, Kurukulasooriya R, Uehara A, Howe S, Ong XM, Tan S, Chow A, Tummalapalli P, De Silva AD, Østbye T, Woods CW, Gubler DJ, and Reller ME
- Subjects
- Acute Disease epidemiology, Adolescent, Adult, Child, Child, Preschool, Cohort Studies, Dengue complications, Dengue epidemiology, Dengue Virus genetics, Dengue Virus isolation & purification, Female, Fever classification, Fever diagnosis, Fever epidemiology, Hospitalization, Humans, Leukopenia epidemiology, Leukopenia etiology, Male, Middle Aged, Polymerase Chain Reaction, Severe Dengue diagnosis, Severe Dengue epidemiology, Severity of Illness Index, Sri Lanka epidemiology, Tertiary Care Centers, Thrombocytopenia epidemiology, Thrombocytopenia etiology, Young Adult, Dengue classification, Dengue diagnosis, Epidemics, World Health Organization
- Abstract
Background: Dengue is a leading cause of fever and mimics other acute febrile illnesses (AFI). In 2009, the World Health Organization (WHO) revised criteria for clinical diagnosis of dengue., Methodology/principal Findings: The new WHO 2009 classification of dengue divides suspected cases into three categories: dengue without warning signs, dengue with warning signs and severe dengue. We evaluated the WHO 2009 classification vs physicians' subjective clinical diagnosis (gestalt clinical impression) in a large cohort of patients presenting to a tertiary care center in southern Sri Lanka hospitalized with acute febrile illness. We confirmed acute dengue in 388 patients (305 adults ≥ 18 years and 83 children), including 103 primary and 245 secondary cases, of 976 patients prospectively enrolled with AFI. At presentation, both adults and children with acute dengue were more likely than those with other AFI to have leukopenia and thrombocytopenia. Additionally, adults were more likely than those with other AFI to have joint pain, higher temperatures, and absence of crackles on examination whereas children with dengue were more likely than others to have sore throat, fatigue, oliguria, and elevated hematocrit and transaminases. Similarly, presence of joint pain, thrombocytopenia, and absence of cough were independently associated with secondary vs primary dengue in adults whereas no variables were different in children. The 2009 WHO dengue classification was more sensitive than physicians' clinical diagnosis for identification of acute dengue (71.5% vs 67.1%), but was less specific. However, despite the absence of on-site diagnostic confirmation of dengue, clinical diagnosis was more sensitive on discharge (75.2%). The 2009 WHO criteria classified almost 75% as having warning signs, even though only 9 (2.3%) patients had evidence of plasma leakage and 16 (4.1%) had evidence of bleeding., Conclusions/significance: In a large cohort with AFI, we identified features predictive of dengue vs other AFI and secondary vs primary dengue in adults versus children. The 2009 WHO dengue classification criteria had high sensitivity but low specificity compared to physicians' gestaldt diagnosis. Large cohort studies will be needed to validate the diagnostic yield of clinical impression and specific features for dengue relative to the 2009 WHO classification criteria.
- Published
- 2018
- Full Text
- View/download PDF
29. Pandemic yellow fever: a potential threat to global health via travelers.
- Author
-
Gubler DJ
- Subjects
- Developing Countries, Endemic Diseases statistics & numerical data, Global Health, Humans, Pandemics statistics & numerical data, Risk Assessment, Travel Medicine, Yellow Fever epidemiology, Yellow Fever Vaccine, Endemic Diseases prevention & control, Pandemics prevention & control, Travel statistics & numerical data, Yellow Fever prevention & control
- Published
- 2018
- Full Text
- View/download PDF
30. History and Emergence of Zika Virus.
- Author
-
Gubler DJ, Vasilakis N, and Musso D
- Subjects
- Africa, Asia, History, 20th Century, History, 21st Century, Humans, Zika Virus Infection epidemiology, Epidemics history, Zika Virus isolation & purification, Zika Virus Infection history
- Abstract
Zika virus was discovered in East Africa in 1947 by the Rockefeller Foundation during investigations on the ecology of yellow fever. Although it was subsequently shown to have widespread distribution in Africa and Asia, it was not known to cause epidemics until 2007. This paper describes the history of the virus discovery, emergence and evolution as an epidemic virus, and the its evolving clinical spectrum., (© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
31. Chymase Level Is a Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients.
- Author
-
Tissera H, Rathore APS, Leong WY, Pike BL, Warkentien TE, Farouk FS, Syenina A, Eong Ooi E, Gubler DJ, Wilder-Smith A, and St John AL
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Risk Assessment, Sri Lanka, Young Adult, Biomarkers blood, Chymases blood, Severe Dengue blood, Severe Dengue physiopathology
- Abstract
Background: Most patients with dengue experience mild disease, dengue fever (DF), while few develop the life-threatening diseases dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). No laboratory tests predict DHF or DSS. We evaluated whether the serum chymase level can predict DHF or DSS in adult and pediatric patients and the influence of preexisting conditions (PECs) on chymase levels., Methods: Serum chymase levels were measured in patients presenting with undifferentiated fever to hospitals in Colombo District, Sri Lanka. The value of serum the chymase concentration and clinical signs and symptoms as predictors of DHF and/or DSS was evaluated by multivariate analysis. We assessed the influence of age, PECs, and day after fever onset on the robustness of the chymase level as a biomarker for DHF and/or DSS., Results: An elevated chymase level in acute phase blood samples was highly indicative of later diagnosis of DHF or DSS for pediatric and adult patients with dengue. No recorded PECs prevented an increase in the chymase level during DHF. However, certain PECs (obesity and cardiac or lung-associated diseases) resulted in a concomitant increase in chymase levels among adult patients with DHF., Conclusions: These results show that patients with acute dengue who present with high levels of serum chymase consistently are at greater risk of DHF. The chymase level is a robust prognostic biomarker of severe dengue for adult and pediatric patients., (© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2017
- Full Text
- View/download PDF
32. An update on Zika virus infection.
- Author
-
Baud D, Gubler DJ, Schaub B, Lanteri MC, and Musso D
- Subjects
- Female, Global Health, Humans, Incidence, Infant, Newborn, Male, Pregnancy, Prognosis, Risk Assessment, Survival Analysis, Zika Virus Infection diagnosis, Communicable Disease Control, Disease Outbreaks, Zika Virus isolation & purification, Zika Virus Infection epidemiology, Zika Virus Infection transmission
- Abstract
The epidemic history of Zika virus began in 2007, with its emergence in Yap Island in the western Pacific, followed in 2013-14 by a larger epidemic in French Polynesia, south Pacific, where the first severe complications and non-vector-borne transmission of the virus were reported. Zika virus emerged in Brazil in 2015 and was declared a national public health emergency after local researchers and physicians reported an increase in microcephaly cases. In 2016, WHO declared the recent cluster of microcephaly cases and other neurological disorders reported in Brazil a global public health emergency. Similar clusters of microcephaly cases were also observed retrospectively in French Polynesia in 2014. In 2015-16, Zika virus continued its spread to cause outbreaks in the Americas and the Pacific, and the first outbreaks were reported in continental USA, Africa, and southeast Asia. Non-vector-borne transmission was confirmed and Zika virus was established as a cause of severe neurological complications in fetuses, neonates, and adults. This Review focuses on important updates and gaps in the knowledge of Zika virus as of early 2017., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
33. Vertebrate Reservoirs of Arboviruses: Myth, Synonym of Amplifier, or Reality?
- Author
-
Kuno G, Mackenzie JS, Junglen S, Hubálek Z, Plyusnin A, and Gubler DJ
- Subjects
- Animals, Arbovirus Infections virology, Culicidae virology, Dengue transmission, Dengue virology, Host Specificity, Humans, Mice, West Nile Fever transmission, Zika Virus Infection transmission, Zika Virus Infection virology, Zoonoses, Arbovirus Infections transmission, Arboviruses isolation & purification, Disease Reservoirs virology, Vertebrates virology
- Abstract
The rapid succession of the pandemic of arbovirus diseases, such as dengue, West Nile fever, chikungunya, and Zika fever, has intensified research on these and other arbovirus diseases worldwide. Investigating the unique mode of vector-borne transmission requires a clear understanding of the roles of vertebrates. One major obstacle to this understanding is the ambiguity of the arbovirus definition originally established by the World Health Organization. The paucity of pertinent information on arbovirus transmission at the time contributed to the notion that vertebrates played the role of reservoir in the arbovirus transmission cycle. Because this notion is a salient feature of the arbovirus definition, it is important to reexamine its validity. This review addresses controversial issues concerning vertebrate reservoirs and their role in arbovirus persistence in nature, examines the genesis of the problem from a historical perspective, discusses various unresolved issues from multiple points of view, assesses the present status of the notion in light of current knowledge, and provides options for a solution to resolve the issue., Competing Interests: The authors declare no conflict of interest.
- Published
- 2017
- Full Text
- View/download PDF
34. Analysis of Dengue Serotype 4 in Sri Lanka during the 2012-2013 Dengue Epidemic.
- Author
-
Uehara A, Tissera HA, Bodinayake CK, Amarasinghe A, Nagahawatte A, Tillekeratne LG, Cui J, Reller ME, Palihawadana P, Gunasena S, Desilva AD, Wilder-Smith A, Gubler DJ, Woods CW, and Sessions OM
- Subjects
- Dengue Virus classification, Humans, Phylogeny, Sri Lanka epidemiology, Dengue epidemiology, Dengue virology, Dengue Virus genetics, Epidemics, Serogroup
- Abstract
The four serotypes of dengue virus (DENV-1, -2, -3, and -4) have had a rapidly expanding geographic range and are now endemic in over 100 tropical and subtropical countries. Sri Lanka has experienced periodic dengue outbreaks since the 1960s, but since 1989 epidemics have become progressively larger and associated with more severe disease. The dominant virus in the 2012 epidemic was DENV-1, but DENV-4 infections were also commonly observed. DENV-4 transmission was first documented in Sri Lanka when it was isolated from a traveler in 1978, but has been comparatively uncommon since dengue surveillance began in the early 1980s. To better understand the molecular epidemiology of DENV-4 infections in Sri Lanka, we conducted whole-genome sequencing on dengue patient samples from two different geographic locations. Phylogenetic analysis indicates that all sequenced DENV-4 strains belong to genotype 1 and are most closely related to DENV-4 viruses previously found in Sri Lanka and those recently found to be circulating in India and Pakistan.
- Published
- 2017
- Full Text
- View/download PDF
35. Peridomestic Aedes malayensis and Aedes albopictus are capable vectors of arboviruses in cities.
- Author
-
Mendenhall IH, Manuel M, Moorthy M, Lee TTM, Low DHW, Missé D, Gubler DJ, Ellis BR, Ooi EE, and Pompon J
- Subjects
- Animals, Cities, Entomology, Humans, Singapore, Aedes growth & development, Aedes virology, Chikungunya virus isolation & purification, Dengue Virus isolation & purification, Mosquito Vectors growth & development, Mosquito Vectors virology, Saliva virology
- Abstract
Background: Dengue and chikungunya are global re-emerging mosquito-borne diseases. In Singapore, sustained vector control coupled with household improvements reduced domestic mosquito populations for the past 45 years, particularly the primary vector Aedes aegypti. However, while disease incidence was low for the first 30 years following vector control implementation, outbreaks have re-emerged in the past 15 years. Epidemiological observations point to the importance of peridomestic infection in areas not targeted by control programs. We investigated the role of vectors in peri-domestic areas., Methods: We carried out entomological surveys to identify the Aedes species present in vegetated sites in highly populated areas and determine whether mosquitoes were present in open-air areas frequented by people. We compared vector competence of Aedes albopictus and Aedes malayensis with Ae. aegypti after oral infection with sympatric dengue serotype 2 and chikungunya viruses. Mosquito saliva was tested for the presence of infectious virus particles as a surrogate for transmission following oral infection., Results: We identified Aedes albopictus and Aedes malayensis throughout Singapore and quantified their presence in forested and opened grassy areas. Both Ae. albopictus and Ae. malayensis can occupy sylvatic niches and were highly susceptible to both arboviruses. A majority of saliva of infected Ae. malayensis contained infectious particles for both viruses., Conclusions: Our study reveals the prevalence of competent vectors in peri-domestic areas, including Ae. malayensis for which we established the vector status. Epidemics can be driven by infection foci, which are epidemiologically enhanced in the context of low herd immunity, selective pressure on arbovirus transmission and the presence of infectious asymptomatic persons, all these conditions being present in Singapore. Learning from Singapore's vector control success that reduced domestic vector populations, but has not sustainably reduced arboviral incidence, we suggest including peri-domestic vectors in the scope of vector management.
- Published
- 2017
- Full Text
- View/download PDF
36. Valine/isoleucine variants drive selective pressure in the VP1 sequence of EV-A71 enteroviruses.
- Author
-
Duy NN, Huong LTT, Ravel P, Huong LTS, Dwivedi A, Sessions OM, Hou Y, Chua R, Kister G, Afelt A, Moulia C, Gubler DJ, Thiem VD, Thanh NTH, Devaux C, Duong TN, Hien NT, Cornillot E, Gavotte L, and Frutos R
- Subjects
- Child, Preschool, Disease Outbreaks, Enterovirus isolation & purification, Enterovirus A, Human isolation & purification, Enterovirus A, Human pathogenicity, Epidemics, Female, Hand, Foot and Mouth Disease epidemiology, Humans, Infant, Isoleucine, Male, Mutation, Phylogeny, Polymorphism, Genetic, Selection, Genetic, Spatio-Temporal Analysis, Valine, Vietnam epidemiology, Capsid Proteins genetics, Enterovirus A, Human genetics, Hand, Foot and Mouth Disease virology
- Abstract
Background: In 2011-2012, Northern Vietnam experienced its first large scale hand foot and mouth disease (HFMD) epidemic. In 2011, a major HFMD epidemic was also reported in South Vietnam with fatal cases. This 2011-2012 outbreak was the first one to occur in North Vietnam providing grounds to study the etiology, origin and dynamic of the disease. We report here the analysis of the VP1 gene of strains isolated throughout North Vietnam during the 2011-2012 outbreak and before., Methods: The VP1 gene of 106 EV-A71 isolates from North Vietnam and 2 from Central Vietnam were sequenced. Sequence alignments were analyzed at the nucleic acid and protein level. Gene polymorphism was also analyzed. A Factorial Correspondence Analysis was performed to correlate amino acid mutations with clinical parameters., Results: The sequences were distributed into four phylogenetic clusters. Three clusters corresponded to the subgenogroup C4 and the last one corresponded to the subgenogroup C5. Each cluster displayed different polymorphism characteristics. Proteins were highly conserved but three sites bearing only Isoleucine (I) or Valine (V) were characterized. The isoleucine/valine variability matched the clusters. Spatiotemporal analysis of the I/V variants showed that all variants which emerged in 2011 and then in 2012 were not the same but were all present in the region prior to the 2011-2012 outbreak. Some correlation was found between certain I/V variants and ethnicity and severity., Conclusions: The 2011-2012 outbreak was not caused by an exogenous strain coming from South Vietnam or elsewhere but by strains already present and circulating at low level in North Vietnam. However, what triggered the outbreak remains unclear. A selective pressure is applied on I/V variants which matches the genetic clusters. I/V variants were shown on other viruses to correlate with pathogenicity. This should be investigated in EV-A71. I/V variants are an easy and efficient way to survey and identify circulating EV-A71 strains.
- Published
- 2017
- Full Text
- View/download PDF
37. Epidemic arboviral diseases: priorities for research and public health.
- Author
-
Wilder-Smith A, Gubler DJ, Weaver SC, Monath TP, Heymann DL, and Scott TW
- Subjects
- Aedes virology, Animals, Dengue Virus, Global Health, Humans, Vaccines economics, Vaccines immunology, Zika Virus, Arbovirus Infections epidemiology, Arbovirus Infections prevention & control, Epidemics prevention & control, Public Health economics, Research economics
- Abstract
For decades, arboviral diseases were considered to be only minor contributors to global mortality and disability. As a result, low priority was given to arbovirus research investment and related public health infrastructure. The past five decades, however, have seen an unprecedented emergence of epidemic arboviral diseases (notably dengue, chikungunya, yellow fever, and Zika virus disease) resulting from the triad of the modern world: urbanisation, globalisation, and international mobility. The public health emergency of Zika virus, and the threat of global spread of yellow fever, combined with the resurgence of dengue and chikungunya, constitute a wake-up call for governments, academia, funders, and WHO to strengthen programmes and enhance research in aedes-transmitted diseases. The common features of these diseases should stimulate similar research themes for diagnostics, vaccines, biological targets and immune responses, environmental determinants, and vector control measures. Combining interventions known to be effective against multiple arboviral diseases will offer the most cost-effective and sustainable strategy for disease reduction. New global alliances are needed to enable the combination of efforts and resources for more effective and timely solutions., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
38. Prevention and control of dengue-the light at the end of the tunnel.
- Author
-
Pang T, Mak TK, and Gubler DJ
- Subjects
- Animals, Dengue Vaccines immunology, Dengue Virus immunology, Humans, Immunization Programs, Mosquito Control methods, Public Health, Vaccination, Dengue drug therapy, Dengue prevention & control, Dengue Vaccines administration & dosage, Insect Vectors virology
- Abstract
Advances in the development of new dengue control tools, including vaccines and vector control, herald a new era of desperately needed dengue prevention and control. The burden of dengue has expanded for decades, and now affects more than 120 countries. Complex, large-scale global forces have and will continue to contribute to the expansion of dengue, including population growth, unplanned urbanisation, and suboptimal mosquito control in urban centres. Although no so-called magic bullets are available, there is new optimism following the first licensure of a dengue vaccine and other promising vaccine candidates, and the development of novel vector control interventions to help control dengue and other expanding mosquito-borne diseases such as Zika virus. Implementation of effective and sustainable immunisation programmes to complement existing methods will add complexity to the health systems of affected countries, which have varying levels of robustness and maturity. Long-term high prioritisation and adequate resources are needed. The way forward is full commitment to addressing a complex disease with a set of solutions integrating vaccination and vector control methods. A whole systems approach is thus needed to integrate these various approaches and strategies for controlling dengue within the goal of universal health coverage. The ultimate objective of these interventions will be to reduce the disease burden in a sustainable and equitable manner., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
39. Mitigating Diseases Transmitted by Aedes Mosquitoes: A Cluster-Randomised Trial of Permethrin-Impregnated School Uniforms.
- Author
-
Kittayapong P, Olanratmanee P, Maskhao P, Byass P, Logan J, Tozan Y, Louis V, Gubler DJ, and Wilder-Smith A
- Subjects
- Adolescent, Aedes physiology, Animals, Chikungunya Fever transmission, Chikungunya Fever virology, Chikungunya virus physiology, Child, Dengue transmission, Dengue virology, Dengue Virus physiology, Female, Humans, Insect Vectors physiology, Male, Schools, Thailand, Zika Virus physiology, Zika Virus Infection transmission, Zika Virus Infection virology, Aedes drug effects, Chikungunya Fever prevention & control, Dengue prevention & control, Insect Vectors drug effects, Insecticides pharmacology, Mosquito Control instrumentation, Mosquito Control methods, Permethrin pharmacology, Protective Clothing, Zika Virus Infection prevention & control
- Abstract
Background: Viral diseases transmitted via Aedes mosquitoes are on the rise, such as Zika, dengue, and chikungunya. Novel tools to mitigate Aedes mosquitoes-transmitted diseases are urgently needed. We tested whether commercially insecticide-impregnated school uniforms can reduce dengue incidence in school children., Methods: We designed a cluster-randomised controlled trial in Thailand. The primary endpoint was laboratory-confirmed dengue infections. Secondary endpoints were school absenteeism; and impregnated uniforms' 1-hour knock-down and 24 hour mosquito mortality as measured by standardised WHOPES bioassay cone tests at baseline and after repeated washing. Furthermore, entomological assessments inside classrooms and in outside areas of schools were conducted., Results: We enrolled 1,811 pupils aged 6-17 from 5 intervention and 5 control schools. Paired serum samples were obtained from 1,655 pupils. In the control schools, 24/641 (3.7%) and in the intervention schools 33/1,014 (3.3%) students had evidence of new dengue infections during one school term (5 months). There was no significant difference in proportions of students having incident dengue infections between the intervention and control schools, with adjustment for clustering by school. WHOPES cone tests showed a 100% knock down and mortality of Aedes aegypti mosquitoes exposed to impregnated clothing at baseline and up to 4 washes, but this efficacy rapidly declined to below 20% after 20 washes, corresponding to a weekly reduction in knock-down and mosquito mortality by 4.7% and 4.4% respectively. Results of the entomological assessments showed that the mean number of Aedes aegypti mosquitoes caught inside the classrooms of the intervention schools was significantly reduced in the month following the introduction of the impregnated uniforms, compared to those collected in classrooms of the control schools (p = 0.04)., Conclusions: Entomological assessments showed that the intervention had some impact on the number of Aedes mosquitoes inside treatment schools immediately after impregnation and before insecticidal activity declined. However, there was no serological evidence of protection against dengue infections over the five months school term, best explained by the rapid washing-out of permethrin after 4 washes. If rapid washing-out of permethrin could be overcome by novel technological approaches, insecticide-treated clothes might become a potentially cost-effective and scalable intervention to protect against diseases transmitted by Aedes mosquitoes such as dengue, Zika, and chikungunya., Trial Registration: ClinicalTrials.gov NCT01563640., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2017
- Full Text
- View/download PDF
40. Emergence of Epidemic Dengue-1 Virus in the Southern Province of Sri Lanka.
- Author
-
Bodinayake CK, Tillekeratne LG, Nagahawatte A, Devasiri V, Kodikara Arachichi W, Strouse JJ, Sessions OM, Kurukulasooriya R, Uehara A, Howe S, Ong XM, Tan S, Chow A, Tummalapalli P, De Silva AD, Østbye T, Woods CW, Gubler DJ, and Reller ME
- Subjects
- Acute Disease, Adolescent, Adult, Antibodies, Viral blood, China epidemiology, Cross-Sectional Studies, Dengue prevention & control, Dengue Virus genetics, Dengue Virus immunology, Disease Outbreaks, Female, Fever, Genotype, Humans, Immunoglobulin G blood, India epidemiology, Male, Rain, Real-Time Polymerase Chain Reaction, Rural Population, Sequence Analysis, DNA, Sri Lanka epidemiology, Travel, Young Adult, Dengue epidemiology, Dengue virology, Dengue Virus isolation & purification, Epidemics statistics & numerical data, Epidemiological Monitoring
- Abstract
Background: Dengue is a frequent cause of acute febrile illness with an expanding global distribution. Since the 1960s, dengue in Sri Lanka has been documented primarily along the heavily urbanized western coast with periodic shifting of serotypes. Outbreaks from 2005-2008 were attributed to a new clade of DENV-3 and more recently to a newly introduced genotype of DENV-1. In 2007, we conducted etiologic surveillance of acute febrile illness in the Southern Province and confirmed dengue in only 6.3% of febrile patients, with no cases of DENV-1 identified. To re-evaluate the importance of dengue as an etiology of acute febrile illness in this region, we renewed fever surveillance in the Southern Province to newly identify and characterize dengue., Methodology/principal Findings: A cross-sectional surveillance study was conducted at the largest tertiary care hospital in the Southern Province from 2012-2013. A total of 976 patients hospitalized with acute undifferentiated fever were enrolled, with 64.3% male and 31.4% children. Convalescent blood samples were collected from 877 (89.6%). Dengue virus isolation, dengue RT-PCR, and paired IgG ELISA were performed. Acute dengue was confirmed as the etiology for 388 (39.8%) of 976 hospitalizations, with most cases (291, 75.0%) confirmed virologically and by multiple methods. Among 351 cases of virologically confirmed dengue, 320 (91.2%) were due to DENV-1. Acute dengue was associated with self-reported rural residence, travel, and months having greatest rainfall. Sequencing of selected dengue viruses revealed that sequences were most closely related to those described from China and Southeast Asia, not nearby India., Conclusions/significance: We describe the first epidemic of DENV-1 in the Southern Province of Sri Lanka in a population known to be susceptible to this serotype because of prior study. Dengue accounted for 40% of acute febrile illnesses in the current study. The emergence of DENV-1 as the foremost serotype in this densely populated but agrarian population highlights the changing epidemiology of dengue and the need for continued surveillance and prevention., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2016
- Full Text
- View/download PDF
41. Dengue infection.
- Author
-
Guzman MG, Gubler DJ, Izquierdo A, Martinez E, and Halstead SB
- Subjects
- Aedes pathogenicity, Aedes virology, Animals, Capillary Permeability physiology, Dengue epidemiology, Dengue Virus immunology, Dengue Virus pathogenicity, Headache etiology, Humans, Insect Vectors virology, Pain etiology, Shock etiology, Thrombocytopenia physiopathology, Tropical Climate adverse effects, Vomiting etiology, Dengue complications, Dengue physiopathology
- Abstract
Dengue is widespread throughout the tropics and local spatial variation in dengue virus transmission is strongly influenced by rainfall, temperature, urbanization and distribution of the principal mosquito vector Aedes aegypti. Currently, endemic dengue virus transmission is reported in the Eastern Mediterranean, American, South-East Asian, Western Pacific and African regions, whereas sporadic local transmission has been reported in Europe and the United States as the result of virus introduction to areas where Ae. aegypti and Aedes albopictus, a secondary vector, occur. The global burden of the disease is not well known, but its epidemiological patterns are alarming for both human health and the global economy. Dengue has been identified as a disease of the future owing to trends toward increased urbanization, scarce water supplies and, possibly, environmental change. According to the WHO, dengue control is technically feasible with coordinated international technical and financial support for national programmes. This Primer provides a general overview on dengue, covering epidemiology, control, disease mechanisms, diagnosis, treatment and research priorities.
- Published
- 2016
- Full Text
- View/download PDF
42. Zika Virus.
- Author
-
Musso D and Gubler DJ
- Subjects
- Animals, Disease Outbreaks, Early Diagnosis, Humans, Insect Vectors virology, Phylogeny, Urban Renewal, Zika Virus classification, Zika Virus Infection epidemiology, Zika Virus Infection transmission, Zika Virus genetics, Zika Virus isolation & purification, Zika Virus Infection diagnosis
- Abstract
Zika virus (ZIKV) is an arthropod-borne virus (arbovirus) in the genus Flavivirus and the family Flaviviridae. ZIKV was first isolated from a nonhuman primate in 1947 and from mosquitoes in 1948 in Africa, and ZIKV infections in humans were sporadic for half a century before emerging in the Pacific and the Americas. ZIKV is usually transmitted by the bite of infected mosquitoes. The clinical presentation of Zika fever is nonspecific and can be misdiagnosed as other infectious diseases, especially those due to arboviruses such as dengue and chikungunya. ZIKV infection was associated with only mild illness prior to the large French Polynesian outbreak in 2013 and 2014, when severe neurological complications were reported, and the emergence in Brazil of a dramatic increase in severe congenital malformations (microcephaly) suspected to be associated with ZIKV. Laboratory diagnosis of Zika fever relies on virus isolation or detection of ZIKV-specific RNA. Serological diagnosis is complicated by cross-reactivity among members of the Flavivirus genus. The adaptation of ZIKV to an urban cycle involving humans and domestic mosquito vectors in tropical areas where dengue is endemic suggests that the incidence of ZIKV infections may be underestimated. There is a high potential for ZIKV emergence in urban centers in the tropics that are infested with competent mosquito vectors such as Aedes aegypti and Aedes albopictus., (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)
- Published
- 2016
- Full Text
- View/download PDF
43. Zika virus: what do we know?
- Author
-
Musso D, Baud D, and Gubler DJ
- Subjects
- Disease Transmission, Infectious, Guillain-Barre Syndrome epidemiology, Guillain-Barre Syndrome etiology, Humans, Microcephaly epidemiology, Microcephaly etiology, Zika Virus Infection complications, Zika Virus Infection transmission, Zika Virus isolation & purification, Zika Virus Infection diagnosis, Zika Virus Infection epidemiology
- Published
- 2016
- Full Text
- View/download PDF
44. Molecular determinants of plaque size as an indicator of dengue virus attenuation.
- Author
-
Goh KC, Tang CK, Norton DC, Gan ES, Tan HC, Sun B, Syenina A, Yousuf A, Ong XM, Kamaraj US, Cheung YB, Gubler DJ, Davidson A, St John AL, Sessions OM, and Ooi EE
- Subjects
- Animals, Cell Line, Cricetinae, Dengue Vaccines adverse effects, Dengue Virus genetics, Dengue Virus growth & development, Dengue Virus immunology, Host-Pathogen Interactions, Humans, Vaccines, Attenuated adverse effects, Virulence, Dengue Virus physiology, Viral Plaque Assay
- Abstract
The development of live viral vaccines relies on empirically derived phenotypic criteria, especially small plaque sizes, to indicate attenuation. However, while some candidate vaccines successfully translated into licensed applications, others have failed safety trials, placing vaccine development on a hit-or-miss trajectory. We examined the determinants of small plaque phenotype in two dengue virus (DENV) vaccine candidates, DENV-3 PGMK30FRhL3, which produced acute febrile illness in vaccine recipients, and DENV-2 PDK53, which has a good clinical safety profile. The reasons behind the failure of PGMK30FRhL3 during phase 1 clinical trial, despite meeting the empirically derived criteria of attenuation, have never been systematically investigated. Using in vitro, in vivo and functional genomics approaches, we examined infections by the vaccine and wild-type DENVs, in order to ascertain the different determinants of plaque size. We show that PGMK30FRhL3 produces small plaques on BHK-21 cells due to its slow in vitro growth rate. In contrast, PDK53 replicates rapidly, but is unable to evade antiviral responses that constrain its spread hence also giving rise to small plaques. Therefore, at least two different molecular mechanisms govern the plaque phenotype; determining which mechanism operates to constrain plaque size may be more informative on the safety of live-attenuated vaccines.
- Published
- 2016
- Full Text
- View/download PDF
45. Yellow fever vaccine supply: a possible solution.
- Author
-
Monath TP, Woodall JP, Gubler DJ, Yuill TM, Mackenzie JS, Martins RM, Reiter P, and Heymann DL
- Subjects
- Dose-Response Relationship, Immunologic, Humans, Vaccination, Yellow Fever prevention & control, Yellow Fever Vaccine supply & distribution
- Published
- 2016
- Full Text
- View/download PDF
46. Laboratory-Enhanced Dengue Sentinel Surveillance in Colombo District, Sri Lanka: 2012-2014.
- Author
-
Tissera H, Amarasinghe A, Gunasena S, DeSilva AD, Yee LW, Sessions O, Muthukuda C, Palihawadana P, Lohr W, Byass P, Gubler DJ, and Wilder-Smith A
- Subjects
- Clinical Laboratory Services, Dengue epidemiology, Dengue virology, Dengue Virus genetics, Dengue Virus isolation & purification, Humans, Laboratories, Hospital, Sensitivity and Specificity, Sri Lanka epidemiology, Dengue diagnosis, Dengue Virus physiology, Diagnostic Tests, Routine methods, Sentinel Surveillance
- Abstract
Introduction: Dengue has emerged as a significant public health problem in Sri Lanka. Historically surveillance was passive, with mandatory dengue notifications based on clinical diagnosis with only limited laboratory confirmation. To obtain more accurate data on the disease burden of dengue, we set up a laboratory-based enhanced sentinel surveillance system in Colombo District. Here we describe the study design and report our findings of enhanced surveillance in the years 2012-2014., Methods: Three outpatient clinics and three government hospitals in Colombo District that covered most of the Colombo metropolitan area were selected for the sentinel surveillance system. Up to 60 patients per week presenting with an undifferentiated fever were enrolled. Acute blood samples from each patient were tested by dengue specific PCR, NS1 ELISA and IgM ELISA. A sub-set of samples was sent to Duke-NUS Singapore for quality assurance, virus isolation and serotyping. Trained medical research assistants used a standardized case report form to record clinical and epidemiological data. Clinical diagnoses by the clinicians-in-charge were recorded for hospitalized cases., Results: Of 3,127 febrile cases, 43.6% were PCR and/or NS1 positive for dengue. A high proportion of lab confirmed dengue was observed from inpatients (IPD) (53.9%) compared to outpatient (clinics in hospitals and general practice) (7.6%). Dengue hemorrhagic fever (DHF) was diagnosed in 11% of patients at the time of first contact, and the median day of illness at time of presentation to the sentinel sites was 4. Dengue serotype 1 was responsible for 85% of the cases and serotype 4 for 15%. The sensitivity and specificity of the clinicians' presumptive diagnosis of dengue was 84% and 34%, respectively., Conclusion: DENV-1, and to a lesser degree DENV-4, infection were responsible for a high proportion of febrile illnesses in Colombo in the years 2012 to 2014. Clinicians' diagnoses were associated with high sensitivity, but laboratory confirmation is required to enhance specificity.
- Published
- 2016
- Full Text
- View/download PDF
47. Beyond efficacy: The full public health impact of vaccines.
- Author
-
Saadatian-Elahi M, Horstick O, Breiman RF, Gessner BD, Gubler DJ, Louis J, Parashar UD, Tapia R, Picot V, Zinsou JA, and Nelson CB
- Subjects
- Congresses as Topic, France, Humans, Licensure, Randomized Controlled Trials as Topic, Public Health, Vaccines standards
- Abstract
There is an active discussion in the public health community on how to assess and incorporate, in addition to safety and measures of protective efficacy, the full public health value of preventive vaccines into the evidence-based decision-making process of vaccine licensure and recommendations for public health use. The conference "Beyond efficacy: the full public health impact of vaccines in addition to efficacy measures in trials" held in Annecy, France (June 22-24, 2015) has addressed this issue and provided recommendations on how to better capture the whole public health impact of vaccines. Using key examples, the expert group stressed that we are in the midst of a new paradigm in vaccine evaluation, where all aspects of public health value of vaccines beyond efficacy should be evaluated. To yield a wider scope of vaccine benefits, additional measures such as vaccine preventable disease incidence, overall efficacy and other outcomes such as under-five mortality or non-etiologically confirmed clinical syndromes should be assessed in addition to traditional efficacy or effectiveness measurements. Dynamic modelling and the use of probe studies should also be considered to provide additional insight to the full public health value of a vaccine. The use of burden reduction and conditional licensure of vaccines based on collection of outcome results should be considered by regulatory agencies., (Copyright © 2016. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
48. Insights into the molecular evolution of Dengue virus type 4 in Puerto Rico over two decades of emergence.
- Author
-
Martin E, Chirivella M, Co JKG, Santiago GA, Gubler DJ, Muñoz-Jordán JL, and Bennett SN
- Subjects
- Dengue epidemiology, Dengue Virus isolation & purification, Genotype, Humans, Molecular Epidemiology, Puerto Rico epidemiology, RNA, Viral genetics, Selection, Genetic, Sequence Analysis, DNA, Viral Envelope Proteins genetics, Viral Nonstructural Proteins genetics, Dengue virology, Dengue Virus classification, Dengue Virus genetics, Evolution, Molecular
- Abstract
Dengue has emerged globally as a major human health problem since the 1950s and is now the most important arboviral disease of humans, infecting nearly 400 million people annually. While some cases are asymptomatic, others can develop a febrile illness (dengue fever) or even progress to severe and fatal dengue. Dengue is caused by any of 4 closely related but distinct viruses, known as Dengue virus serotype 1 to 4 (DENV-1 to DENV-4) which are maintained in endemic transmission to humans in large urban centers of the tropics by Aedes mosquitoes. Since the early 1960s, Puerto Rico, a major metropolitan center in the Caribbean, has experienced increasingly larger and clinically more severe epidemics following the introduction of all four dengue serotypes. The first dengue hemorrhagic fever epidemic in 1986, and a particularly severe outbreak in 1998 were dominated by novel DENV-4 strains that evolved in Puerto Rico, replacing earlier strains and spreading throughout the region. Sequence characterization of 54 complete DENV-4 genomes and their comparative evolution against 74 previously published viral sequences from the region over several decades shows that DENV-4 strains from these periods were genetically distinct based on unique changes in the envelope and non-structural genes. Their replacement of earlier strains in Puerto Rico progressed rapidly, suggesting that strong natural selection played a role in their fixation. This study confirms that DENVs evolve through rapid lineage turnover driven in part by natural selection and genetic drift., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
49. Production of Infectious Dengue Virus in Aedes aegypti Is Dependent on the Ubiquitin Proteasome Pathway.
- Author
-
Choy MM, Sessions OM, Gubler DJ, and Ooi EE
- Subjects
- Animal Structures virology, Animals, Female, Gene Knockdown Techniques, RNA, Viral biosynthesis, Viral Load, Aedes virology, Dengue Virus growth & development, Host-Pathogen Interactions, Proteasome Endopeptidase Complex metabolism, Ubiquitin metabolism
- Abstract
Dengue virus (DENV) relies on host factors to complete its life cycle in its mosquito host for subsequent transmission to humans. DENV first establishes infection in the midgut of Aedes aegypti and spreads to various mosquito organs for lifelong infection. Curiously, studies have shown that infectious DENV titers peak and decrease thereafter in the midgut despite relatively stable viral genome levels. However, the mechanisms that regulate this decoupling of infectious virion production from viral RNA replication have never been determined. We show here that the ubiquitin proteasome pathway (UPP) plays an important role in regulating infectious DENV production. Using RNA interference studies, we show in vivo that knockdown of selected UPP components reduced infectious virus production without altering viral RNA replication in the midgut. Furthermore, this decoupling effect could also be observed after RNAi knockdown in the head/thorax of the mosquito, which otherwise showed direct correlation between infectious DENV titer and viral RNA levels. The dependence on the UPP for successful DENV production is further reinforced by the observed up-regulation of key UPP molecules upon DENV infection that overcome the relatively low expression of these genes after a blood meal. Collectively, our findings indicate an important role for the UPP in regulating DENV production in the mosquito vector.
- Published
- 2015
- Full Text
- View/download PDF
50. PUBLIC HEALTH. Dengue vaccines at a crossroad.
- Author
-
Wilder-Smith A and Gubler DJ
- Subjects
- Child, Child, Preschool, Communicable Disease Control methods, Dengue epidemiology, Dengue Vaccines administration & dosage, Hospitalization statistics & numerical data, Humans, Public Health, Dengue prevention & control, Dengue Vaccines immunology
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.